These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 26119837)
1. The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions. Aronson JK; Ferner RE Br J Clin Pharmacol; 2016 Jan; 81(1):56-61. PubMed ID: 26119837 [TBL] [Abstract][Full Text] [Related]
3. Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. Ferner RE; Aronson JK Br J Clin Pharmacol; 2016 Jan; 81(1):52-5. PubMed ID: 26174880 [TBL] [Abstract][Full Text] [Related]
4. Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review. Iammatteo M; Blumenthal KG; Saff R; Long AA; Banerji A J Allergy Clin Immunol Pract; 2014; 2(6):768-74. PubMed ID: 25439369 [TBL] [Abstract][Full Text] [Related]
5. Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions. Aronson JK; Ferner RE Drug Saf; 2010 Nov; 33(11):995-1002. PubMed ID: 20925437 [TBL] [Abstract][Full Text] [Related]
6. Biomarkers of adverse drug reactions. Carr DF; Pirmohamed M Exp Biol Med (Maywood); 2018 Feb; 243(3):291-299. PubMed ID: 28950720 [TBL] [Abstract][Full Text] [Related]
7. Reclassifying Anaphylaxis to Neuromuscular Blocking Agents Based on the Presumed Patho-Mechanism: IgE-Mediated, Pharmacological Adverse Reaction or "Innate Hypersensitivity"? Spoerl D; Nigolian H; Czarnetzki C; Harr T Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28590439 [TBL] [Abstract][Full Text] [Related]
8. Concentration-dependent mechanisms of adverse drug reactions in epilepsy. Vázquez M; Fagiolino P; Mariño EL Curr Pharm Des; 2013; 19(38):6802-8. PubMed ID: 23530511 [TBL] [Abstract][Full Text] [Related]
9. Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Chan BS; Buckley NA Clin Toxicol (Phila); 2014; 52(8):824-36. PubMed ID: 25089630 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of unpredictable adverse drug reactions. Rieder MJ Drug Saf; 1994 Sep; 11(3):196-212. PubMed ID: 7811401 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules. Shah RR Expert Opin Drug Saf; 2005 Jan; 4(1):103-28. PubMed ID: 15709902 [TBL] [Abstract][Full Text] [Related]
12. Ways to minimize adverse drug reactions. Individualized doses and common sense are key. Cohen JS Postgrad Med; 1999 Sep; 106(3):163-8, 171-2. PubMed ID: 10494273 [TBL] [Abstract][Full Text] [Related]
13. Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic). Iasella CJ; Johnson HJ; Dunn MA Clin Liver Dis; 2017 Feb; 21(1):73-87. PubMed ID: 27842776 [TBL] [Abstract][Full Text] [Related]
14. Do standard doses of frequently prescribed drugs cause preventable adverse effects in women? Cohen JS J Am Med Womens Assoc (1972); 2002; 57(2):105-10, 114. PubMed ID: 11991418 [TBL] [Abstract][Full Text] [Related]
15. Drug-induced hypersensitivity: role in drug development. Ratajczak HV Toxicol Rev; 2004; 23(4):265-80. PubMed ID: 15898831 [TBL] [Abstract][Full Text] [Related]
16. Potential use of data-mining algorithms for the detection of 'surprise' adverse drug reactions. Hauben M; Horn S; Reich L Drug Saf; 2007; 30(2):143-55. PubMed ID: 17253879 [TBL] [Abstract][Full Text] [Related]
17. Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning. Callréus T Drug Saf; 2006; 29(7):557-66. PubMed ID: 16808549 [TBL] [Abstract][Full Text] [Related]